Harmony Biosciences Holdings, Inc. (HRMY)

29.03 -0.28 (-0.96%) 收市：04:00PM EDT

Harmony Biosciences Holdings, Inc.

630 West Germantown Pike
Suite 215
Plymouth Meeting, PA 19462
United States
484 539 9800
https://www.harmonybiosciences.com

版塊: Healthcare
行業: Biotechnology
全職員工: 246

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jeffrey S. Aronin	Founder & Non-Executive Chairman	185.67k	無	1968
Dr. Jeffrey M. Dayno M.D.	President, CEO & Director	1.26M	無	1957
Mr. Sandip S. Kapadia CPA, M.B.A.	Executive VP, Chief Administrative Officer & CFO	813.52k	無	1970
Mr. David Bradshaw	Head of Technical Operations	無	無	無
Luis Sanay	Head of Investor Relations	無	無	無
Mr. Christian Ulrich	General Counsel & Corporate Secretary	無	無	無
Ms. Tricia Glover	Chief Compliance Officer	無	無	無
Ms. Audrey Murphy SPHR	Vice Presidet of Human Resources	無	無	無
Ms. Cate McCanless	Head of Corporate Affairs & Public Policy	無	無	無
Ms. Kelli Wright	Senior Manager of Patient Advocacy & Harmony Biosciences	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

公司管治

截至 2024年5月1日 止，Harmony Biosciences Holdings, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：7；董事會：9；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。